Epidiolex Cannabidiol: Phase II/III started

GW began a double-blind, placebo-controlled, U.S. Phase II/III trial of 5, 10 and 20 mg/kg/day oral Epidiolex in children who are being treated with other anti-epileptic drugs. In the initial dose-fin...